Literature DB >> 30308386

Activation against absenteeism - Evidence from a sickness insurance reform in Norway.

Øystein Hernæs1.   

Abstract

I evaluate a program aimed at strictly enforcing a requirement that people on long-term sick leave be partly back at work unless explicitly defined as an exception. Employing the synthetic control method, I find that the reform reduced work-hours lost due to sickness absenteeism by 12% in the reform region compared to a comparison unit created by a weighted average of similar regions. The effect is driven by both increased part-time presence of temporary disabled workers and accelerated recovery. Musculoskeletal disorders was the diagnosis group declining the most. The findings imply large savings in social security expenditures.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Absenteeism; Activation; Disability; Workfare

Mesh:

Year:  2018        PMID: 30308386     DOI: 10.1016/j.jhealeco.2018.09.007

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  3 in total

1.  Has the share of the working life expectancy that is spent receiving a partial or full disability pension changed in Finland over the period 2005-2018? A longitudinal register-based study.

Authors:  Taina Leinonen; Eira Viikari-Juntura; Svetlana Solovieva
Journal:  BMJ Open       Date:  2022-07-14       Impact factor: 3.006

2.  Associations of employment sector and occupational exposures with full and part-time sickness absence: random and fixed effects analyses on panel data.

Authors:  Elli Hartikainen; Svetlana Solovieva; Eira Viikari-Juntura; Taina Leinonen
Journal:  Scand J Work Environ Health       Date:  2021-12-01       Impact factor: 5.492

3.  What is the effect of independent medical evaluation on days on sickness benefits for long-term sick listed employees in Norway? A pragmatic randomised controlled trial, the NIME-trial.

Authors:  Silje Mæland; Tor Helge Holmås; Irene Øyeflaten; Elisabeth Husabø; Erik L Werner; Karin Monstad
Journal:  BMC Public Health       Date:  2022-02-26       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.